You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit
SBC: SILICON CURES LLC Topic: NINRPROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Digital Cognitive Screening Test to detect Mild Cognitive Impairment and Dementia in Clinical Settings.
SBC: EchoWear LLC Topic: NIAProject Summary Alzheimer’s disease and related dementias are a growing health problem in our aging population. Assessment of cognitive functioning for early detection is critical to identify individuals who might benefit from treatment with the available symptomatic medications for mild dementia as well as future disease-modifying therapies that are actively under development and being tested i ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy
SBC: BOLDEN THERAPEUTICS, INC. Topic: RPROJECT SUMMARY Alzheimer's disease (AD) is a looming public health crisis that threatens millions of patients' ability to experience healthy aging. In addition to the challenges that AD poses to patients, healthcare providers and caregivers, there is also tremendous economic burden associated with AD and related dementias – estimated to be well over $200B/year in the United States alone. Hundre ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of a Targeted Radiotherapeuitc for Pancreatic Ductal Adenocarcinoma
SBC: ADDUCTNE LLC Topic: 102In 2020 alone, pancreatic cancer is estimated to have resulted in 47,050 deaths in the U.S. making it the fourth leading cause of cancer-related death. Pancreatic ductal adenocarcinoma (PDAC) makes up greater than 90% of all pancreatic cancer diagnoses and has an overall five-year survival rate of just 10%. New therapeutic options are needed to improve the poor prognosis for patients with PDAC. Ex ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Antioxidant enzyme-loaded Pro-NP for treatment of TBI.
SBC: PROTRANSIT NANOTHERAPY LLC Topic: 106ABSTRACT Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide and comes with a significant economic burden associated with emergency room visits and hospitalizations. Oxidative stress- mediated secondary injury post-TBI is a considerable risk factor for mortality and long-term impairment. Immediately following TBI, a cascade of biological responses leads to i ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization
SBC: Breezmed Topic: 104ABSTRACT This STTR Phase I project uses mixed-method formative evaluation strategies to develop, test, and evaluate an alpha prototype of Breezmed, a point-of-care electronic prior authorization web-based platform. Prior authorization burdens the current medical system, hampering a provider’s ability to efficiently prescribe medication and in a timely fashion. This often leads to treatment non-c ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Developing Nanopieces, a Platform RNAi Delivery Technology for Treatment of Multiple Diseases
SBC: Nanode Therapeutics, Inc. Topic: NCATSSTTR_Developing Nanopieces 7. Project Summary/Abstract The bottleneck of developing new RNAi (RNA Interference) drugs is the lack of highly efficient and non-toxic RNA delivery to non-liver tissues in vivo. It is especially challenging to deliver negatively-charged nucleic acid into avascular, dense, and negatively-charged matrix in hard-to-reach tissues including joint cartilage. NanoDe Therapeut ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel High-Resolution Scintillation X-ray Detectors for Digital Dentistry
SBC: NGS Detectors LLC Topic: NIDCRProject SummaryNovel High Resolution Scintillation X ray Detectors for Digital Dentistry The transition from traditional film to digital X ray detectors has resulted in significant improvements across many areas for dental X ray imaging ranging from decreased wait timesimproved logistics and even lower radiation dose ratesOne significant drawback remains with digital X ray imaging howeverwhich is ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Personalized Bioreactor for Cell Culturing in Alginate Tubes
SBC: CellGro Technologies, LLC Topic: 400PROJECT SUMMARY ABSTRACT SignificanceCell therapy is expected to become an important method to treat chronic diseases such as diabetesrheumatoid arthritisretinal diseases like macular degeneration and certain types of cancersThe cell therapy market in general is projected to become a $billion industry byHuman pluripotent stem cellshPSCsare of particular importance since their utility as a source f ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression
SBC: Aingeal, LLC Topic: 101Major depressive disorder is a debilitating mood disorder that affects ~7% of US adults in their lifetime, costing the U.S. economy more than $200 billion a year. Drugs that increase monoaminergic signaling are the mainstay of depression therapy, but have a delayed onset of action and are only effective in about 50% of affected patients. Aberrant brain-derived neurotrophic factor (BDNF) signaling ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health